decamethonium has been researched along with Myasthenia Gravis in 6 studies
decamethonium: RN given refers to parent cpd
decamethonium : A quaternary ammonium ion that is a depolarising muscle relaxant whose structure comprises a decane-1,10-diamine core in which each amino group carries three methyl substituents.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this paper is to indicate improvement in mortality and morbidity due to three major advances: (1) use of the decamethonium diagnostic test in a myasthenia gravis clinic; (2) improvements in assessment and management of respiratory insufficiency; and (3) avoidance of anticholinesterase treatment in the immediate and early postoperative recovery period." | 3.64 | MYASTHENIA GRAVIS: ANESTHETIC AND SURGICAL MANAGEMENT OF THE PATIENT UNDERGOING THYMECTOMY. ( CHANG, J; JENKINS, LC; SAXTON, GD, 1965) |
| "The diagnosis of myasthenia gravis is often difficult and calls for a broader use of pharmacological and electrodiagnostic tests." | 1.24 | MYASTHENIA GRAVIS: MEDICAL ASPECTS. ( BUCKLER, WS; ZELDOWICZ, LR, 1965) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| PELIKAN, EW | 1 |
| TETHER, JE | 1 |
| UNNA, KR | 1 |
| ROSS, RT | 1 |
| ZELDOWICZ, LR | 1 |
| BUCKLER, WS | 1 |
| JENKINS, LC | 1 |
| CHANG, J | 1 |
| SAXTON, GD | 1 |
| CHURCHILL-DAVIDSON, HC | 1 |
| RICHARDSON, AT | 1 |
| Vernet-der-Garabédian, B | 1 |
| Morel, E | 1 |
| Bach, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Electrophysiological Comparison of mAP and mADM Using EMG[NCT03360825] | 56 participants (Actual) | Observational | 2017-11-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for decamethonium and Myasthenia Gravis
| Article | Year |
|---|---|
Sensitivity of myasthenia gravis patients to tubocurarine and decamethonium.
Topics: Curare; Decamethonium Compounds; Humans; Muscle Relaxants, Central; Myasthenia Gravis; Tubocurarine | 1953 |
THE EFFECT OF DECAMETHONIUM ON CURARE SENSITIVE OCULAR MYOPATHY.
Topics: Curare; Decamethonium Compounds; Diagnosis, Differential; Drug Hypersensitivity; Electromyography; E | 1964 |
MYASTHENIA GRAVIS: MEDICAL ASPECTS.
Topics: Acetylcholine; Botulism; Bromides; Cholinesterase Inhibitors; Decamethonium Compounds; Diagnosis; Di | 1965 |
MYASTHENIA GRAVIS: ANESTHETIC AND SURGICAL MANAGEMENT OF THE PATIENT UNDERGOING THYMECTOMY.
Topics: Anesthesia; Anesthetics; Cholinesterase Inhibitors; Decamethonium Compounds; Drug Therapy; Humans; M | 1965 |
The action of decamethonium iodide (C.10) in myasthenia gravis.
Topics: Decamethonium Compounds; Humans; Muscle Relaxants, Central; Myasthenia Gravis | 1952 |
[Heterogeneity of antibodies blocking the binding of bungarotoxin to the acetylcholine receptor in myasthenia].
Topics: Antibodies; Bungarotoxins; Decamethonium Compounds; Humans; Kinetics; Myasthenia Gravis; Radioimmuno | 1984 |